SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the Rodman &
Biocept to Present at the 103rd AACR Annual Meeting on New Analytic Methods for Circulating Tumor Cell Analysis, Including SelectorTM, Ultra-Sensitive Mutation Detection Technology San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on
SAN DIEGO , Sept. 30, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall , Biocept President and CEO, is scheduled to
SAN DIEGO , April 6, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a leading molecular diagnostics company that commercializes and develops liquid biopsy tests for cancer profiling and monitoring, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview
SAN DIEGO , Feb. 6, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the management of cancer patients, announces that President and CEO Michael W. Nall will present a corporate overview at the 19 th
SAN DIEGO , Feb. 4, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.
SAN DIEGO , March 15, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that David Moskowitz , Vice President of Strategy
SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to
SAN DIEGO , March 7, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael W.
SAN DIEGO , March 8, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W.